SCHEMBL333664

SCHEMBL333664

O=C(O)Cc1c(C(=O)O)c2cc(Oc3ccc(F)c(Cl)c3)ccc2n1-c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.46
USP14 P54578 1/20 0.43
MAPT P10636 3/20 0.42
TP53 P04637 2/20 0.42
THRB P10828 2/20 0.42
HIF1A Q16665 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HTT P42858 1/20 0.40
PPARG P37231 2/20 0.39
GAA P10253 1/20 0.38
GFER P55789 1/20 0.38
AGTR1 P30556 1/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
REN P00797 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL333989 0.92 KDM4E (0.46) KDM4EUSP14MAPTTP53THRB
SCHEMBL334162 0.89 USP14 (0.52) KDM4EUSP14MAPTTP53THRB
SCHEMBL333835 0.88 KDM4E (0.47) KDM4EUSP14MAPTTP53THRB
SCHEMBL333222 0.82 PPARG (0.47) KDM4EUSP14MAPTSMN1; SMN2ALDH1A1
SCHEMBL1407175 0.81 PPARG (0.39) KDM4EUSP14TP53THRBHIF1A
SCHEMBL332701 0.81 MEN1 (0.38) KDM4EUSP14MAPTTP53THRB
SCHEMBL334194 0.81 PPARG (0.45) KDM4EUSP14PPARG
SCHEMBL10051928 0.80 KDM4E (0.57) KDM4EUSP14MAPTTP53HIF1A
SCHEMBL334287 0.80 FFAR1 (0.43) KDM4EUSP14MAPTTP53THRB
SCHEMBL333611 0.80 PPARG (0.47) KDM4EUSP14MAPTHIF1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097623-B2 1-Aryl-or heteroaryl-3-aryl-or heteroarylindole-2-carboxylic acids or esters: e.g., 5-(4-tert-Butylphenyl)-1,3-bis(4-isopropoxyphenyl)-indole-2-carboxylic acid; inhibition of the activity of microsomal prostaglandin E synthase-1, leukotriene C4 and/or 5-lipoxygenase-activating protein; analgesics BIOLIPOX AB (SE) 2012-01-17 US disclosed
EP-1841735-B1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2011-03-09 EP disclosed
US-20090076004-A1 Indoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2009-03-19 US disclosed
CN-101142185-A Indoles useful in the treatment of inflammation BIOLIPOX AB (SE) 2008-03-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076004-A1 Indoles Useful in the Treatment of Inflammation IDO1, IDO2, AREG KDM4E 1104/4885USP14 3873/4885MAPT 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.